+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6085417
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Understanding the Current State of Blastic-Phase CML Treatment

Blastic-phase chronic myeloid leukemia represents the most aggressive and high-risk transformation of chronic myeloid leukemia, characterized by rapid disease progression and significant treatment challenges. Patients in this advanced stage face a sharply elevated risk of morbidity and mortality, underscoring the pressing need for more effective therapeutic strategies. Recent years have seen a proliferation of novel agents and combination regimens, reflecting the intense research focus on overcoming drug resistance mechanisms and improving overall survival.

This executive summary distills key findings from a rigorous market research report on blastic-phase CML treatments, offering stakeholders a clear view of emerging therapeutic modalities, shifting regulatory landscapes, and evolving access considerations. It synthesizes insights on major segmentation drivers, regional dynamics, competitive positioning, and policy impacts that are reshaping the treatment paradigm. By providing a concise yet comprehensive overview, this summary equips decision-makers with the knowledge required to align product strategies, investment priorities, and commercial approaches with the latest industry developments.

Emerging Shifts Reshaping the Treatment Landscape

The blastic-phase CML treatment landscape is undergoing transformative shifts fueled by scientific breakthroughs and real-world evidence adoption. A notable trend is the emergence of targeted small molecule inhibitors that overcome resistance mutations once deemed untreatable. Concurrently, immunomodulatory approaches are gaining traction, with early clinical data showing promise in restoring anti-leukemic immunity.

The integration of combination therapies has further redefined response expectations, as dual- or triple-agent regimens harness synergistic mechanisms to achieve deeper remissions. Enhanced diagnostic precision, driven by next-generation sequencing and digital pathology, empowers clinicians to tailor therapies according to specific genetic and immunophenotypic profiles. These innovations are complemented by an increased emphasis on patient-reported outcomes and quality-of-life measures, which are now influencing regulatory approvals and reimbursement decisions.

Together, these developments are shifting treatment paradigms from one-size-fits-all to precision-guided protocols, heralding a new era in which personalized medicine becomes the standard of care for blastic-phase CML patients.

Assessing the Impact of US Tariff Changes on Treatment Accessibility

The introduction of new United States tariff measures slated for 2025 poses significant implications for the blastic-phase CML market. Tariffs on key active pharmaceutical ingredients and specialized excipients may drive up production costs for both established and emerging therapies. Manufacturers are anticipated to reassess their supply chain footprints, potentially relocating or diversifying sourcing strategies to mitigate cost pressures.

Pricing and reimbursement negotiations will likely be influenced as healthcare payers seek to contain budgets in the face of higher list prices. Patients could experience delays in access to critical medications unless stakeholders proactively engage in value-based contracting or seek alternative distribution pathways. Conversely, some market entrants may capitalize on localization incentives, forging partnerships with US-based contract manufacturers to benefit from tariff exemptions.

In this evolving policy environment, agile commercial and regulatory strategies will be essential to maintain treatment affordability and continuity of supply. Early stakeholder alignment, scenario planning, and cost-of-goods optimization will collectively determine which therapies remain accessible to the patient population most in need.

Deciphering Market Trends Through Comprehensive Segmentation

Segmentation by Treatment Type reveals that small molecule inhibitors continue to command the largest share of therapeutic regimens, driven by robust efficacy against prevalent Bcr-Abl mutations. Monoclonal antibodies, though newer to the market, are registering accelerated uptake in combination protocols due to their targeted immune engagement. Meanwhile, combination therapies themselves are gaining momentum as clinical trial data validate synergistic benefits over monotherapies.

In the realm of Therapy Line, first-line options now increasingly favor next-generation Bcr-Abl inhibitors that offer deeper molecular responses and improved tolerability. Second-line treatments are diversifying, with immunomodulators and chemo-immunotherapy combinations filling gaps created by resistance to frontline agents. Third-line and beyond options remain a critical area of unmet need, prompting innovation in bispecific antibodies and novel targeted agents.

Mechanism Of Action segmentation underscores the sustained dominance of Bcr-Abl inhibitors, complemented by chemotherapy agents that provide salvage options in refractory cases. Immunomodulators are carving out a growing niche as adjunctive therapies, bolstered by positive early-phase results demonstrating enhanced survival.

When viewed through Route Of Administration, oral formulations drive patient convenience and adherence, yet intravenous regimens retain their role in rapid debulking and inpatient settings. This dichotomy underscores the importance of flexible dosing options tailored to disease severity.

End User analysis shows that hospitals remain the primary treatment sites due to necessary supportive care infrastructure, while specialty clinics are expanding outpatient capacity. Ambulatory surgical centers are increasingly integrating infusion services, reflecting broader shifts toward decentralized oncology care.

Distribution Channel insights indicate that hospital pharmacies distribute the majority of blastic-phase CML therapies, yet retail pharmacies are growing their share for oral options, and online pharmacies are emerging as viable channels for direct-to-patient delivery.

Finally, Patient Age Group splits demonstrate that adults constitute the bulk of the patient base, though pediatric cases-albeit rarer-demand specialized dosing protocols and safety monitoring frameworks.

Regional Variations Driving Treatment Dynamics

The Americas region leads in adoption of cutting-edge blastic-phase CML therapies, supported by strong regulatory alignment and expansive reimbursement frameworks. The United States market, in particular, showcases rapid incorporation of next-generation inhibitors and real-world evidence programs that accelerate formulary inclusion. Latin American markets are gradually enhancing access via public-private partnerships and compassionate use schemes.

In Europe, Middle East & Africa, the landscape is more heterogeneous. European Union member states exhibit structured health technology assessment pathways that prioritize high-value treatments, while certain Middle Eastern countries leverage centralized procurement to negotiate competitive pricing. Sub-Saharan Africa and other emerging markets face significant access barriers, prompting philanthropic and non-profit initiatives to bridge gaps in care delivery.

Asia-Pacific presents a dynamic growth narrative underpinned by expanding healthcare infrastructure and increasing disease awareness. Japan’s stringent regulatory process is complemented by robust clinical research networks, whereas China’s localized manufacturing capabilities are driving cost efficiencies. Southeast Asian nations are progressively updating leukemia treatment guidelines, and patient advocacy groups are catalyzing improvements in diagnostic reach and therapeutic access.

Innovators and Leaders Shaping Therapeutic Advances

Several leading pharmaceutical companies are at the forefront of blastic-phase CML innovation, each leveraging distinct strategic imperatives. One global innovator has solidified its position by expanding its portfolio of next-generation Bcr-Abl inhibitors and investing heavily in real-world outcome studies to support reimbursement dossiers. Another multinational entity has pursued strategic acquisitions of biotech firms specializing in bispecific antibodies, aiming to integrate novel immunotherapeutics into its oncology arm.

Mid-sized biopharma organizations are differentiating through nimble clinical development programs, targeting third-line and beyond indications with first-in-class compounds. Partnerships between established players and emerging biotech firms are proliferating, enabling the rapid co-development of combination regimens and sharing of specialized manufacturing capabilities. Across the competitive landscape, emphasis on patient-centric services-ranging from digital adherence tools to nurse-led support lines-has become a key differentiator among companies vying for market share.

Strategic Actions to Navigate the Evolving CML Landscape

To navigate the complexities of the blastic-phase CML market, industry leaders should prioritize precision medicine approaches by investing in diagnostic technologies that stratify patients according to molecular profiles. Collaborative partnerships between pharmaceutical companies, diagnostic developers, and healthcare providers can accelerate co-development of companion diagnostics and targeted therapies.

Engaging payers early in the evidence generation process will strengthen value propositions, especially for high-cost therapies facing tariff-driven price pressures. Companies should also explore outcomes-based contracting models that align reimbursement with real-world patient benefits. Optimizing supply chains through regional manufacturing hubs can mitigate the impact of US tariff changes, ensuring continuity of supply and cost containment.

Finally, robust patient support programs, incorporating digital adherence tracking and telehealth consultations, will enhance treatment persistence and quality of life, positioning companies as partners in patient care rather than mere product suppliers.

Rigorous Methods Underpinning Our Analysis

This report is grounded in a multi-stage research methodology combining extensive secondary research with primary data collection to validate market dynamics. The secondary phase included a comprehensive review of scientific literature, regulatory filings, clinical trial registries, and industry publications to map the therapeutic landscape and identify emerging trends.

Primary research involved in-depth interviews with key opinion leaders, including hematologists, oncologists, health economists, and payer representatives. Insights from these experts were synthesized with quantitative data on clinical outcomes, treatment utilization patterns, and distribution practices. Robust data triangulation ensured that findings reflect consensus viewpoints and real-world experiences.

All qualitative and quantitative inputs underwent iterative validation through an advisory panel of specialists. This rigorous approach underpins the report’s credibility, offering stakeholders a reliable foundation for strategic decision-making.

Summarizing Key Takeaways for Stakeholders

Blastic-phase CML treatment continues to evolve rapidly, driven by innovations in targeted therapies, immunomodulation, and diagnostic precision. Key segmentation and regional insights highlight areas of opportunity, from optimizing first-line regimens to addressing unmet needs in later lines of therapy and underserved geographies.

The cumulative impact of regulatory and policy shifts-including forthcoming US tariffs-will require agile strategies to balance cost pressures with patient access imperatives. Competitive dynamics underscore the importance of strategic alliances, value-based contracting, and patient-centric service models in differentiating offerings.

By synthesizing these multifaceted insights, stakeholders can chart a clear path forward, harnessing scientific advances and market intelligence to improve outcomes for patients facing this formidable disease transformation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Combination Therapies
    • Monoclonal Antibodies
    • Small Molecule Inhibitors
  • Therapy Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • Mechanism Of Action
    • Bcr-Abl Inhibitors
    • Chemotherapy Agents
    • Immunomodulators
  • Route Of Administration
    • Intravenous
    • Oral
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Age Group
    • Adults
    • Pediatrics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sandoz International GmbH
  • Lupin Limited
  • Hikma Pharmaceuticals PLC

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Treatment of Blastic-Phase CML Market, by Treatment Type
8.1. Introduction
8.2. Combination Therapies
8.3. Monoclonal Antibodies
8.4. Small Molecule Inhibitors
9. Treatment of Blastic-Phase CML Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Treatment of Blastic-Phase CML Market, by Mechanism Of Action
10.1. Introduction
10.2. Bcr-Abl Inhibitors
10.3. Chemotherapy Agents
10.4. Immunomodulators
11. Treatment of Blastic-Phase CML Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Treatment of Blastic-Phase CML Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Treatment of Blastic-Phase CML Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Treatment of Blastic-Phase CML Market, by Patient Age Group
14.1. Introduction
14.2. Adults
14.3. Pediatrics
15. Americas Treatment of Blastic-Phase CML Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Treatment of Blastic-Phase CML Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Treatment of Blastic-Phase CML Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Bristol-Myers Squibb Company
18.3.3. Pfizer Inc.
18.3.4. Takeda Pharmaceutical Company Limited
18.3.5. Sun Pharmaceutical Industries Limited
18.3.6. Teva Pharmaceutical Industries Limited
18.3.7. Viatris Inc.
18.3.8. Sandoz International GmbH
18.3.9. Lupin Limited
18.3.10. Hikma Pharmaceuticals PLC
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TREATMENT OF BLASTIC-PHASE CML MARKET MULTI-CURRENCY
FIGURE 2. TREATMENT OF BLASTIC-PHASE CML MARKET MULTI-LANGUAGE
FIGURE 3. TREATMENT OF BLASTIC-PHASE CML MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TREATMENT OF BLASTIC-PHASE CML MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TREATMENT OF BLASTIC-PHASE CML MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TREATMENT OF BLASTIC-PHASE CML MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 50. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 51. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 114. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 121. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 149. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 163. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 164. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 198. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 210. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 219. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 241. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 248. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 249. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 255. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 283. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 284. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DIS

Companies Mentioned

The companies profiled in this Treatment of Blastic-Phase CML market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sandoz International GmbH
  • Lupin Limited
  • Hikma Pharmaceuticals PLC

Methodology

Loading
LOADING...

Related Topics

Related Reports

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Blastic Plasmacytoid Dendritic Cell Neoplasm Market by Treatment Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Blastic Plasmacytoid Dendritic Cell Neoplasm Market by Treatment Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Malignancy - Pipeline Insight, 2025 - Product Image

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Malignancy - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Stem Cell Transplantation), By End Use (Hospitals, Specialty Clinics), And Segment Forecasts, 2024 - 2030 - Product Image

Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Stem Cell Transplantation), By End Use (Hospitals, Specialty Clinics), And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Blastic Plasmacytoid Dendritic Cell Neoplasm - Global Strategic Business Report - Product Image

Blastic Plasmacytoid Dendritic Cell Neoplasm - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.